RealFeedApp Rivus to present RV-8451 data at ObesityWeek 2026
Rivus Pharmaceuticals will display preclinical data for RV-8451 at ObesityWeek 2026. The oral GLP-1 agonist is designed to target fat while preserving muscle mass in non-human primate and mouse models.
- Field
- ageing and longevity
- What they did
- Rivus Pharmaceuticals plans to present preliminary data on its pill RV-8451 at the ObesityWeek conference in November 2026. The data, obtained from non-human primate and mouse models, concern a new oral GLP-1 receptor agonist.
- Why it matters
- Researchers hope this drug will help people lose weight without losing muscle mass, which is a key drawback of many existing medications.
#glp-1#muscle sparing#obesity#rivus#preclinical
